UK Renal Registry 19th Annual Report:Chapter 4 Demography of the UK Paediatric Renal Replacement Therapy Population in 2015 by Hamilton, Alexander et al.
                          Hamilton, A., Braddon, F., Casula, A., Lewis, M., Mallett, T., Marks, S., ...
Maxwell, H. (2017). UK Renal Registry 19th Annual Report: Chapter 4
Demography of the UK Paediatric Renal Replacement Therapy Population in
2015. Nephron, 137 Suppl 1, 103-116. https://doi.org/10.1159/000481366
Publisher's PDF, also known as Version of record
License (if available):
CC BY-NC-ND
Link to published version (if available):
10.1159/000481366
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Karger at DOI:
10.1159/000481366 . Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
UK Renal Registry 19th Annual Report:
Chapter 4 Demography of the UK
Paediatric Renal Replacement Therapy
Population in 2015
Alexander J Hamiltonab, Fiona Braddona, Anna Casulaa, Malcolm Lewisc,
Tamara Mallettd, Stephen D Markse, Mohan Shenoyf, Manish D Sinhag, Yincent Tseh,
Heather Maxwelli
aUK Renal Registry, Bristol, UK; bUniversity of Bristol, Bristol, UK; cOur Lady’s Children’s Hospital, Crumlin, Ireland;
dBristol Royal Hospital for Children, Bristol, UK; eGreat Ormond Street Hospital for Children NHS Foundation Trust,
London, UK; fRoyal Manchester Children’s Hospital, Manchester, UK; gEvelina London Children’s Hospital, London, UK;
hGreat North Children’s Hospital, Newcastle Upon Tyne, UK; iRoyal Hospital for Children, Glasgow, UK
Keywords
Adolescents . Aetiology . Children . Demography . Estab-
lished renal failure . Incidence . Prevalence . Pre-emptive
transplantation . Renal replacement therapy . Survival .
Young adults
Summary
. A total of 941 children and young people aged ,18
years with established renal failure (ERF) were
receiving treatment at paediatric nephrology centres
in 2015.
. At the census date (31st December 2015), 75.3% of
prevalent paediatric patients aged ,16 years had a
functioning kidney transplant, 13.0% were receiving
haemodialysis (HD) and 11.7% were receiving
peritoneal dialysis (PD).
. In patients aged ,16 years, prevalence of ERF was
62.7 per million age related population (pmarp)
and incidence was 10.2 pmarp.
. The most common primary renal diagnosis was
renal dysplasia+ reﬂux, present in 34.7% of preva-
lent paediatric patients aged ,16 years.
. A quarter of patients aged ,16 years had one or
more reported comorbidities at onset of renal
replacement therapy (RRT).
. Pre-emptive transplantation rates for children aged
three months to 16 years who were referred early
have been maintained and were 33.2% for the
2011–2015 period.
. At transfer to adult services, 89.4% of patients had a
functioning kidney transplant.
. Survival during childhood among children com-
mencing RRT was the lowest in those aged under
two years compared to those aged 12 to ,16
years, with a hazard ratio of 4.1 (conﬁdence interval
[CI] 1.7–9.9) and in those receiving dialysis com-
pared to having a functioning transplant, with a
hazard ratio of 6.5 (CI 3.4–12.6).
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Introduction
The UK Renal Registry (UKRR) publishes annually
chapters detailing demographics, clinical, haematological
and biochemical parameters for patients managed in
UK paediatric nephrology centres. In the UK, care for
children, adolescents and young adults with established
renal failure (ERF) requiring renal replacement therapy
(RRT) is a tertiary service provided in 13 paediatric
nephrology centres. All centres are equipped to provide
peritoneal dialysis (PD) and haemodialysis (HD), with
10 centres also undertaking kidney transplantation.
Young adults aged 16–18 years may be managed in
either paediatric or adult services, depending on local
practices, educational and social factors. In this report,
data for all patients aged ,18 years in UK paediatric
nephrology centres reported to the UKRR (with a par-
ticular focus on the demographics of those aged ,16
years) are described.
In the UK in 2014, the prevalence rate of treated ERF
in children and adolescents aged ,16 years was 60.4 per
million age related population (pmarp) and the incidence
rate was 9.4 pmarp [1].
The objectives of this chapter are:
1. To describe the UK incidence, prevalence, causes of
ERF and modality of treatment of children, adoles-
cents and young adults on RRT on 31st December
2015
2. To describe trends in (1) over the past 15 years
3. To describe pre-emptive transplantation rates and
survival of children and adolescents on RRT aged
,16 years in the UK.
All 13 paediatric nephrology centres in the UK con-
tribute data to the UKRR, mandated in England by the
NHS service speciﬁcation which requires, ‘paediatric
renal units to submit data comprising the national
renal data set to the UK Renal Registry on all patients
on renal replacement therapy’ [2]. In most cases this is
via an annual extract of a centre’s clinical computer
system which is checked, validated and loaded onto the
UKRR paediatric database. Where this is not possible,
data returns are completed using a data collection form
and manually loaded. At each return, missing data
items are sought. Centres pay a capitation fee in order
to support the process. Currently, the UKRR paediatric
and adult databases are maintained separately and a
future merger is planned.
Methods
Centres arranged for their own data to be extracted and sent to
the UKRR for processing by clinical informaticians. For this
report, end of year numbers were required by 31st January 2016
and the full data by 31st March 2016. However, the last submission
was received on 4th September 2016. Overall responsibility for the
process is held by the chair of the British Association for Paediatric
Nephrology (BAPN) Audit and Registry Committee.
The content and analyses contained in the paediatric chapters
are discussed and agreed by the BAPN Audit and Registry Com-
mittee members.
In this report, patient groups are described as:
1. ‘Incident’ group: patients who started RRT between
1st January and 31st December 2015
2. ‘Prevalent’ group: patients who were receiving RRT on
31st December 2015
3. ‘Five-year’ groups: patients who started RRT in the periods
of 2001–2005, 2006–2010 and 2011–2015.
RRT is deﬁned as all patients with renal transplants and
patients on HD and PD for 90 days or more, with dialysis for
acute kidney injury (AKI) not reported upon at present. In this
report those aged ,16 years at start of RRT who had received at
least 90 days of RRT are included. Data for those aged 16–18
years and those receiving RRT for ,90 days are not currently
uniformly submitted to the UKRR.
The populations used to calculate the incidence and prevalence
were obtained from the Ofﬁce for National Statistics (ONS) [3].
The mid-2015 population estimate produced by the ONS, based
on the 2011 census, was used to calculate the 2015 incidence
and prevalence; the 2003 census data were used for the 2001–
2005 group, the 2008 data for the 2006–2010 group and the
2013 data for the 2011–2015 group. Incidence and prevalence
for 16–18 year olds are not reported. This is because data would
not be representative of the UK as a whole, because these young
people may also be managed in adult services.
Ethnicity is deﬁned as stated by the patient/family and is
reported as White, South Asian, Black and Other. The ‘South
Asian’ ethnicity includes those of Indian, Pakistani or Bangladeshi
origin only. The ‘Other’ ethnicity includes those from Chinese,
other South Asian groups, e.g. Vietnamese and Malaysian, Arabic,
mixed race ethnic origin or any other group. ‘Black’ ethnicity
includes those of ‘Black-African’, ‘Black-Caribbean’ origin and
‘Black-other’ groups.
Statistical analyses were performed using SAS 9.3, with group
analyses using the chi-squared test and median analyses using
the Kruskal-Wallis test. Infants under the age of three months
and ‘late presenters’ (deﬁned as those commencing dialysis within
three months following ﬁrst review by a paediatric nephrologist)
were excluded from analyses when calculating pre-emptive trans-
plantation rates. For survival analysis, only patients starting RRT
between 1st January 2001 and 31st December 2014 and receiving
RRT for at least 90 days were included to ensure a minimum of
one year follow-up at the census date. These patients were fol-
lowed up to a maximum age of 16 years. As the maximum age
of follow-up was restricted to 16 years it was not possible to calcu-
late 10-year survival probabilities for patients starting RRT aged
over eight years, or ﬁve-year survival probability for children
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starting RRT aged.12 years. A Cox regression model was used to
calculate hazard ratios for patient survival, adjusting for gender,
age at start of RRT and RRT modality as a time dependent
variable. Survival probabilities were calculated using univariate
Kaplan-Meier curves.
Results
Data returns
Centres used a variety of clinical data systems to
facilitate returns. In 2015, the majority of paediatric
renal centres were using Vitaldata (Birmingham, Cardiff,
Glasgow, Leeds, London Great Ormond Street), with
others using Clinicalvision (Manchester, Newcastle),
Mediqal (Belfast, Nottingham), Proton (Bristol), Cyber-
REN (Liverpool) or bespoke systems (London Evelina,
Southampton).
Most centres submitted their 2015 data electronically
(N = 12) to the UKRR via data extracts. The remaining
centre used paper forms which were manually entered
into the database.
Overall data completeness was excellent for the follow-
ing: age and gender (100%), ethnicity (98.0%), start and
90-day treatment modality (99.7%) and start date
(99.5%). Completeness of other data items ranged from
83.4% to 99.2% and is shown by centre in table 4.1.
Centre size and type (if undertaking paediatric kidney
transplantation) are also displayed.
The UK paediatric prevalent ERF population in 2015
A total of 941 children and young people aged ,18
years with ERF were receiving treatment at paediatric
nephrology centres in 2015 (table 4.1). Of these, 769
(81.7%) were ,16 years of age. Table 4.2 shows the
number of these patients receiving RRT and rate of
RRT by age group and gender. There was more than
ten times the number of teenagers than infants receiving
RRT. The prevalence of RRT increased with age and was
higher in males across all age groups with an overall male
to female ratio of 1.7 : 1.0. The reported prevalence in
,16 year olds was 62.7 pmarp.
Table 4.3 shows the prevalence of ERF in under 16 year
olds by ethnicity. Children from ethnic minorities dis-
played higher RRT prevalence rates when compared
with White children, with South Asian children exhibit-
ing the highest rates.
Modality of treatment
The majority of prevalent paediatric patients under 16
years old in 2015 had a functioning transplant, as shown
in ﬁgure 4.1. The ratio of living to deceased donor trans-
plants was 1.0 : 0.8.
Forty-four percent of patients started RRT on PD, 33%
on HD and 23% with a pre-emptive transplant, as dis-
played in ﬁgure 4.2.
Analysis by age shows the proportion of those receiv-
ing dialysis as current treatment was higher in younger
children, with increasing use of transplantation in older
Table 4.1. Data completeness for the paediatric prevalent ERF population on 31/12/2015
% completeness
Centre N
First seen
date
Height at
RRT start
Weight at
RRT start
Creatinine at
RRT start
Primary renal
diagnosis
Blfst_P∗ 25 92.0 80.0 88.0 92.0 100.0
Bham_P∗ 110 93.6 92.7 94.6 94.6 99.1
Brstl_P∗ 56 96.4 87.5 94.6 98.2 100.0
Cardf_P 31 93.6 96.8 96.8 96.8 100.0
Glasg_P∗ 56 100.0 96.4 100.0 98.2 100.0
L Eve_P∗ 100 84.0 60.0 66.0 68.0 100.0
L GOSH_P∗ 179 96.7 88.3 93.9 96.1 100.0
Leeds_P∗ 82 100.0 90.2 100.0 100.0 100.0
Livpl_P 56 94.6 69.6 76.8 91.1 96.4
Manch_P∗ 91 94.5 92.3 95.6 95.6 100.0
Newc_P∗ 36 100.0 97.2 97.2 100.0 100.0
Nottm_P∗ 87 95.4 73.6 89.7 87.4 94.3
Soton_P 32 93.8 50.0 50.0 59.4 100.0
UK 941 94.8 83.4 89.3 91.2 99.2
RRT – renal replacement therapy
∗Denotes centre undertaking kidney transplantation for children
Demography of UK paediatric RRT
population
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patients, as shown in table 4.4. There were no transplants
in those aged under two years and live transplants were
more common than deceased transplants in those aged
two to under 12 years. Treatment in the youngest age
groups was subject to variation because there were few
patients. There was no difference in modality by gender
or ethnicity.
Cause of ERF
Renal dysplasia with or without reﬂux nephropathy
was the commonest primary renal diagnosis (PRD) in
prevalent patients under 16 years in 2015 as shown in
table 4.5. The high male to female ratio in those with
obstructive uropathy was a result of posterior urethral
valves. Figure 4.3 displays the percentage of patients in
Table 4.2. The UK paediatric prevalent ERF population ,16 years old on 31/12/2015, by age group and gender
Age group (years)
All patients Males Females
M : F rate
ratioN pmarp N pmarp N pmarp
0–,2 21 13.4 13 16.2 8 10.5 1.5
2–,4 55 33.5 40 47.6 15 18.7 2.5
4–,8 185 57.2 126 76.1 59 37.3 2.0
8–,12 231 77.2 143 93.3 88 60.2 1.5
12–,16 277 98.1 172 118.9 105 76.2 1.6
Under 16 769 62.7 494 78.7 275 46.0 1.7
pmarp – per million age related population
Table 4.3. The UK paediatric prevalent ERF population ,16 years old on 31/12/2015, by age group and ethnic groupa
Age group (years)
White South Asian Black Otherb
N pmarp N pmarp N pmarp N
0–,4 52 20.1 11 52.2 2 23.7 9
4–,8 132 55.2 25 128.2 3 38.5 21
8–,12 163 63.7 46 220.7 8 95.9 12
12–,16 200 74.2 43 195.8 16 182.1 16
Under 16 547 53.5 125 149.9 29 86.9 58
pmarp – per million age related population
aTen children with no ethnicity data recorded are excluded from this table
bpmarp data not included for group ‘Other’, because the group is too heterogeneous
HD
13%
PD
12%
Deceased donor
transplant
34%
Live transplant
41%
Fig. 4.1. RRT treatment used by prevalent paediatric patients
,16 years old on 31/12/2015
HD
33%
PD
44%
Deceased donor
transplant
8%
Live transplant
15%
Fig. 4.2. Treatment modality at start of RRT in prevalent paedia-
tric patients ,16 years old on 31/12/2015
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each diagnostic category for incident and prevalent
cohorts. Missing PRD data have remained low: 0.4% in
2011 [4] to 0.8% in 2015.
The commonest comorbidities at the onset of RRT in
2015 were congenital abnormalities, developmental delay
and syndromic diagnoses, reported in 7.0%, 6.9% and
6.5% of patients respectively, as shown in table 4.6.
Although the majority of children were reported to
have no comorbidities, there was considerable variation
between centres (e.g. no comorbidity reported in 94%
of patients from Cardiff and 50% of patients from
Bristol). This may be due to small numbers in some
centres or reporting practice and will be subject to a
data quality exercise to evaluate whether there are
genuine differences between centres in their willingness
to accept patients with comorbidities onto the RRT
programme.
Table 4.4. Current treatment modality by age group in the UK paediatric prevalent ERF population ,18 years old on 31/12/2015
Age group
(years) Total
Current treatment
HD PD Live transplant Deceased donor transplant
N % N % N % N %
0–,2 21 5 23.8 16 76.2 0 0.0 0 0.0
2–,4 55 16 29.1 24 43.6 13 23.6 2 3.6
4–,8 185 25 13.5 18 9.7 102 55.1 40 21.6
8–,12 231 30 13.0 14 6.1 97 42.0 90 39.0
12–,16 277 24 8.7 18 6.5 108 39.0 127 45.8
16–,18 172 9 5.2 10 5.8 68 39.5 85 49.4
Under 16 769 100 13.0 90 11.7 320 41.6 259 33.7
Under 18 941 109 11.6 100 10.6 388 41.2 344 36.6
HD – haemodialysis; PD – peritoneal dialysis
Table 4.5. Number, percentage and gender by primary renal disease in the UK paediatric prevalent ERF population ,16 years old
on 31/12/2015∗
Diagnostic group N % Males Females M : F ratio
Renal dysplasia+ reﬂux 267 34.7 172 95 1.8
Obstructive uropathy 145 18.9 142 3 47.3
Glomerular disease 88 11.4 37 51 0.7
Congenital nephrotic syndrome 77 10.0 40 37 1.1
Tubulo-interstitial diseases 51 6.6 21 30 0.7
Renovascular disease 37 4.8 25 12 2.1
Polycystic kidney disease 33 4.3 15 18 0.8
Metabolic 29 3.8 18 11 1.6
Uncertain aetiology 19 2.5 13 6 2.2
Malignancy & associated disease 17 2.2 5 12 0.4
Missing 6 0.8 6 0
Total 769 494 275 1.8
∗In 2015 there were no patients with ERF secondary to ‘drug nephrotoxicity’
0  10  20  30  40
Percentage of patients
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ea
se
Malignancy &
associated disease
Uncertain aetiology
Metabolic
Polycystic kidney disease
Renovascular disease
Tubulo-interstitial disease 
Congenital nephrotic
syndrome
Glomerular disease
Obstructive uropathy
Renal dysplasia ± reflux
Prevalent
Incident
Fig. 4.3. Primary renal disease percentage in the UK paediatric
incident and prevalent ERF population ,16 years old in 2015
for patients with a reported causative diagnosis
Demography of UK paediatric RRT
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The UK paediatric incident ERF population in 2015
There were 137 patients ,18 years of age who com-
menced RRT at paediatric renal centres in 2015. As
before, the following analyses were restricted to the 125
patients who were ,16 years of age.
The incidence of RRT was 10.2 pmarp in 2015.
Patients commencing RRT in 2015 are displayed by age
and gender in table 4.7; apparent differences may be a
result of small group sizes.
Trends in ERF demographics
Table 4.8 shows that the reported incidence of RRT
has remained steady since 2001, with the highest inci-
dence seen in both the youngest and oldest age groups.
There were 1,715 children and adolescents ,16 years
of age who had received RRT in the UK over the 15-
year period between 2001 and 2015. Table 4.9 shows an
increase in the proportion of those aged two to ,four
years starting RRT and a decrease in the proportion of
those aged 12 to ,16 years starting RRT over the time
period. Table 4.10 shows a decrease in the proportion
of those with a White ethnicity starting RRT and an
increase in the proportion of those in the ‘Other’ ethnic
group starting RRT over the time period. Table 4.11
shows that the overall proportions between paediatric
renal centres have ﬂuctuated only slightly over the time
period.
Table 4.12 shows the number and percentage of chil-
dren receiving RRT with each of the major reported
comorbidities over the last 15 years. As before, any appar-
ent differences may be a result of small numbers between
groups. Overall, less comorbidity has been reported in
children receiving RRT over the last 15 years and, as
previously mentioned, it is not clear whether this was
due to reporting or differences in case selection.
The proportion of those starting RRT with deceased
donor transplants is falling (from 12.0% in 2001–2005
to 8.6% in 2011–2015), as shown in ﬁgure 4.4, whilst
Table 4.6. Frequency of registered comorbidities at onset of
RRT in the UK paediatric prevalent ERF population ,16 years
old in 2015
Comorbidity N
% all RRT
patients
Congenital abnormality 54 7.0
Developmental delay 53 6.9
Syndromic diagnosis 50 6.5
Prematurity 46 6.0
Consanguinity 26 3.4
Liver disease 12 1.6
Chromosomal abnormality 11 1.4
Family member with ERF 11 1.4
Cerebral palsy 8 1.0
Congenital heart disease 7 0.9
Malignancy 6 0.8
Neural tube defect 4 0.5
Psychological disorder 4 0.5
Diabetes 1 0.1
No reported comorbidity 571 74.3
One reported comorbidity 128 16.6
Two or more comorbidities 70 9.1
Table 4.7. The UK paediatric incident ERF population ,16 years old in 2015, by age group and gender
Age group (years)
All patients Males Females
M : F ratioN pmarp N pmarp N pmarp
0–,2 22 14.1 16 20.0 6 7.9 2.5
2–,4 14 8.5 10 11.9 4 5.0 2.4
4–,8 34 10.5 21 12.7 13 8.2 1.5
8–,12 26 8.7 14 9.1 12 8.2 1.1
12–,16 29 10.3 17 11.8 12 8.7 1.3
Under 16 125 10.2 78 12.4 47 7.9 1.6
pmarp – per million age related population
Table 4.8. Reported average incidence by age group in ﬁve-year
time periods of the UK paediatric incident ERF population ,16
years old commencing RRT
Age group
(years)
pmarp
2001–2005 2006–2010 2011–2015
0–,2 12.4 13.1 12.1
2–,4 5.8 7.3 9.4
4–,8 5.7 6.9 6.9
8–,12 8.1 8.9 9.5
12–,16 13.1 14.4 11.7
Under 16 9.1 10.2 9.7
pmarp – per million age related population
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that of live transplants has remained stable in the two
most recent ﬁve-year periods (17.8%). As seen previously,
use of PD as a starting modality has fallen from 53.0% in
2001–2005 to 36.8% in 2011–2015, being replaced with
increased use of HD and living kidney donation.
Glomerular disease as a cause of ERF has fallen
compared to other PRDs in the prevalent paediatric
population over the last 15 years, as shown in table 4.13.
Pre-emptive transplantation
Of the 1,715 patients aged,16 years who started RRT
between 2001 and 2015, 463 were excluded from this
Table 4.9. Number and percentage of the UK paediatric incident ERF population ,16 years old who commenced RRT, by age
group and ﬁve-year period of starting RRT
Age group (years)
2001–2005 2006–2010 2011–2015
N % N % N %
0–,2 83 15.6 101 16.9 98 16.8
2–,4 39 7.3 53 8.9 76 13.0
4–,8 83 15.6 95 15.9 107 18.3
8–,12 123 23.1 129 21.6 133 22.8
12–,16 205 38.5 220 36.8 170 29.1
Under 16 533 598 584
Table 4.10. Number∗ and percentage of the UK paediatric incident ERF population ,16 years old who commenced RRT, by
ethnicity and ﬁve-year period of starting RRT
Ethnic group
2001–2005 2006–2010 2011–2015
N % N % N %
White 418 78.7 445 75.3 399 69.6
South Asian 81 15.3 93 15.7 102 17.8
Black 14 2.6 24 4.1 20 3.5
Other 18 3.4 29 4.9 52 9.1
Under 16 531 591 573
∗Two children in 2001–2005, seven in 2006–2010 and 11 in 2011–2015 with no ethnicity recorded are excluded from this table
Table 4.11. Number and percentage of the UK paediatric incident ERF population ,16 years old, by renal centre and ﬁve-year
period of starting RRT
Centre
2001–2005 2006–2010 2011–2015
N % N % N %
Blfst_P 17 3.2 24 4.0 13 2.2
Bham_P 54 10.1 66 11.0 70 12.0
Brstl_P 41 7.7 34 5.7 32 5.5
Cardf_P 16 3.0 19 3.2 24 4.1
Glasg_P 33 6.2 44 7.4 39 6.7
L Eve_P 44 8.3 65 10.9 63 10.8
L GOSH_P 97 18.2 121 20.2 99 17.0
Leeds_P 50 9.4 53 8.9 53 9.1
Livpl_P 31 5.8 21 3.5 35 6.0
Manch_P 52 9.8 47 7.9 68 11.6
Newc_P 30 5.6 25 4.2 20 3.4
Nottm_P 47 8.8 63 10.5 47 8.0
Soton_P 21 3.9 16 2.7 21 3.6
Under 16 533 598 584
Demography of UK paediatric RRT
population
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analysis (92 patients due to being aged under three
months, 371 due to being late presenters). Table 4.14
shows that a third of the 1,252 patients identiﬁed as
being aged three months to ,16 years and starting
RRT between 2001–2015 had a pre-emptive transplant.
Contrary to previous reports [1], there was no signiﬁ-
cant difference in pre-emptive transplantation rates by
time period (p = 0.09).
There remained a signiﬁcant difference in pre-emptive
transplantation rates, with higher rates in boys (p =
0.002), although this difference was less signiﬁcant
(p = 0.03) when adjusted for other factors in a logistic
regression (time period, ethnicity, age at start and
PRD). Pre-emptive transplantation rates were higher in
White versus non-White ethnicity (p , 0.0001). Analysis
by age at start of RRT showed that, as expected, the lowest
Table 4.12. Trends in reported comorbidity frequency at the onset of RRT in the UK paediatric incident population ,16 years old,
by ﬁve-year period
Comorbidity
2001–2005 2006–2010 2011–2015
N % N % N %
Syndromic diagnosis 49 9.2 45 7.5 31 5.3
Developmental delay 38 7.1 44 7.4 30 5.1
Congenital abnormality 48 9.0 48 8.0 29 5.0
Prematurity 26 4.9 31 5.2 27 4.6
Consanguinity 21 3.9 16 2.7 19 3.3
Family member with ERF 22 4.1 11 1.8 13 2.2
Liver disease 10 1.9 11 1.8 8 1.4
Malignancy 8 1.5 3 0.5 5 0.9
Neural tube defect 3 0.6 4 0.7 5 0.9
Cerebral palsy 9 1.7 9 1.5 4 0.7
Congenital heart disease 12 2.3 19 3.2 4 0.7
Psychological disorder 10 1.9 8 1.3 4 0.7
Chromosomal abnormality 12 2.3 20 3.3 2 0.3
Diabetes 6 1.1 3 0.5 1 0.2
No reported comorbidity 336 63.0 419 70.1 457 78.3
One reported comorbidity 140 26.3 119 19.9 84 14.4
Two or more comorbidities 57 10.7 60 10.0 43 7.4
ERF – established renal failure
HD PD Deceased donor
transplant
Live transplant
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Fig. 4.4. Treatment modality at start of RRT
for the UK paediatric incident ERF
population ,16 years old, by ﬁve-year time
period
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rate of pre-emptive transplantation was in those aged
three months to two years, whilst children aged four to
16 years had similar rates of pre-emptive transplantation.
Following exclusion of the youngest age group, there was
no statistical difference in pre-emptive transplantation
rates by age. Rates differed with PRD (lower in glomeru-
lar diseases versus renal dysplasia+ reﬂux nephropathy
and obstructive uropathies, p, 0.0001). Children with
polycystic kidney disease, obstructive uropathy, meta-
bolic causes, renal dysplasia+ reﬂux, uncertain aetiology
and renovascular diseases had the highest rates of pre-
emptive transplantation, whilst those with malignancy
and congenital nephrotic syndrome had the lowest rates.
Transfer of patients to adult renal services in 2015
Eighty-ﬁve patients were reported by paediatric
nephrology centres to have transferred to adult renal
services in 2015, similar to the 93 who transferred during
2014 [1]. The median age of patients transferred out was
18.0 years with an inter-quartile range of 17.7–18.4 years.
Table 4.15 shows that the demographics of those transfer-
ring out were very similar to those of the overall prevalent
paediatric RRT population, but with 89.4% having a
functioning transplant.
Survival of children on RRT during childhood
Of patients under 16 years of age, 1,561 were identiﬁed
as starting RRT between 2001 and 2014 at paediatric
centres in the UK and were included in the survival
analyses. At the census date (31st December 2015) there
were a total of 75 deaths reported in children on RRT
,16 years of age at paediatric centres. The median follow
up time (beyond day 90) was 3.4 years (range of three days
to 14.7 years). Table 4.16 shows the survival hazard ratios
(following adjustment for age at start of RRT, gender and
RRT modality) and highlights that children starting RRT
under two years of age had the worst survival outcomes,
with a hazard ratio of 4.1 (CI 1.7–9.9, p = 0.002) when
compared to 12–16 year olds. Being on dialysis was
shown to lower survival signiﬁcantly compared to having
a functioning transplant, with a hazard ratio of 6.5
(CI 3.4–12.6, p, 0.0001). There was insufﬁcient power
to add PRD to the model; drug induced nephrotoxicity
and metabolic PRDs had the worst survival but CIs
were wide and included no effect. Figure 4.5 shows unad-
justed Kaplan-Meier survival probabilities and highlights
worse outcomes for those aged less than two years,
particularly during the ﬁrst year.
Mortality data in 2015
Nine deaths occurred in paediatric renal centres in
2015; the median age at death was 10.7 years (range
3.1–17.8 years). In children aged ,18 years with treated
ERF, the total reported mortality in 2015 in UK paediatric
centres was 1.0% (9/941) and 5.5% (6/109) for those on
dialysis.
Transplant deaths
In 2015, at the time of death, four children had
received a kidney transplant. One child had a sudden
unexplained death. The causes of death for the other
three children were: malignant hyperthermia; viraemia
and multiorgan failure; and an acute haematological
malignancy.
Table 4.13. Number∗ and percentage of primary renal diseases in the UK paediatric prevalent ERF population ,16 years old, by
ﬁve-year time period
Primary renal diagnosis
2001–2005 2006–2010 2011–2015
N % N % N %
Renal dysplasia+ reﬂux 172 32.6 193 32.7 204 35.4
Obstructive uropathy 77 14.6 92 15.6 96 16.6
Glomerular disease 112 21.3 124 21.0 71 12.3
Tubulo-interstitial diseases 41 7.8 46 7.8 47 8.1
Congenital nephrotic syndrome 27 5.1 32 5.4 46 8.0
Uncertain aetiology 20 3.8 26 4.4 30 5.2
Polycystic kidney disease 15 2.8 14 2.4 26 4.5
Metabolic 26 4.9 30 5.1 26 4.5
Renovascular disease 18 3.4 22 3.7 22 3.8
Malignancy & associated disease 10 1.9 7 1.2 9 1.6
Drug nephrotoxicity 9 1.7 4 0.7 0 0.0
∗Six children in 2001–2005, eight in 2006–2010 and seven in 2011–2015 with no primary renal diagnosis recorded are excluded from this
table
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Dialysis deaths
In 2015, at the time of death, ﬁve children were on
dialysis (all HD). Two patients died due to malignancy,
two due to septicaemia and another due to cardiac failure
on the background of a metabolic disorder.
Discussion
This report provides the paediatric nephrology com-
munity with a unique resource of data on the demo-
graphics of the UK paediatric RRT population from the
previous year, as well as allowing comparisons of trends
over the last ﬁfteen years. This information is vital for
the commissioning of such a tertiary service and the
data are also included in European registry reports to
allow for international comparisons.
Data returns
Paediatric nephrology in the UK faces the challenge
of being mandated to submit electronic data on small
numbers of patients to the UKRR, sometimes using
renal computer systems designed to collect registry data
for adult patients. This often results in the need for
additional data collection for the paediatric-speciﬁc
dataset. Overall, completeness of data items has fallen
slightly. In spite of this all centres are included. Despite
a standardised dataset, the extracts received by the
UKRR usually require extensive input to allow them to
be uploaded into the database. Once submitted data
have been checked and validated they are returned to
Table 4.14. Demographic characteristics of pre-emptive trans-
plantation in the UK paediatric ERF population aged three
months to 16 years, 2001–2015, by ﬁve-year time period, gender,
ethnicity, age at start of RRT and PRD
N
N (%)
pre-emptively
transplanted
Total cohort analysed (2001–2015) 1,252 417 (33.3)
Time period
2001–2005 389 115 (29.6)
2006–2010 420 155 (36.9)
2011–2015 443 147 (33.2)
Gender
Male 791 288 (36.4)
Female 461 129 (28.0)
Ethnicity
White 918 333 (36.3)
South Asian 207 46 (22.2)
Other 68 24 (35.3)
Black 40 6 (15.0)
Age at start of RRT (years)
3 months–,2 134 7 (5.2)
2–,4 143 41 (28.7)
4–,8 226 93 (41.2)
8–,12 298 104 (34.9)
12–,16 451 172 (38.1)
Primary renal diagnosis
Renal dysplasia+ reﬂux 438 185 (42.2)
Obstructive uropathy 226 105 (46.5)
Glomerular disease 204 25 (12.3)
Congenital nephrotic syndrome 87 4 (4.6)
Tubulo-interstitial diseases 78 16 (20.5)
Metabolic 66 29 (43.9)
Polycystic kidney disease 46 23 (50.0)
Renovascular disease 37 12 (32.4)
Uncertain aetiology 31 11 (35.5)
Malignancy & associated disease 16 1 (6.3)
Drug nephrotoxicity 5 1 (20.0)
Table 4.15. Modality, gender, ethnicity and PRD of the UK
paediatric ERF population ,18 years old transferred out from
paediatric nephrology centres to adult renal services in 2015
N %
Modality
Transplant 76 89.4
HD 5 5.9
PD 4 4.7
Gender
Male 52 61.2
Female 33 38.8
Ethnicitya
White 58 69.9
South Asian 15 18.1
Other 7 8.4
Black 3 3.6
Primary renal diagnosisbc
Renal dysplasia+ reﬂux 28 33.3
Glomerular disease 15 17.9
Obstructive uropathy 11 13.1
Tubulo-interstitial diseases 7 8.3
Congenital nephrotic syndrome 7 8.3
Polycystic kidney disease 6 7.1
Metabolic 4 4.8
Uncertain aetiology 3 3.6
Malignancy & associated disease 2 2.4
Renovascular disease 1 1.2
aTwo children with no ethnicity recorded are excluded from this table
bOne child with no primary renal diagnosis recorded is excluded
from this table
cIn 2015 there were no patients transferred out with ‘drug nephro-
toxicity’
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submitting renal centres with the onus on clinicians to
provide any missing data items. A system is being devised
to mark unobtainable missing data and to write them off,
thereby minimising requests to clinicians. Feedback on
improving the process is always welcomed.
Highlights from the 2015 data
Incident and prevalent rates remained steady. Overall
the prevalent population was largely White, male and
predominantly aged over eight years, with a functioning
transplant, although the proportion of those commen-
cing RRT aged two to under four years and from ethnic
minorities was increasing.
RRT start modality
PD remained the most frequent start modality in just
under half of paediatric patients. However, since 2001,
use of PD as a start treatment is falling, with pre-emptive
live transplants and HD increasing. PD was still the most
commonly used RRT modality in young children. It is
encouraging that a third of patients are now being pre-
emptively transplanted, with increased use of live
transplants that rate was stable in the two most recent
ﬁve-year periods. Pre-emptive transplantation was
observed to be inﬂuenced by ethnicity and PRD. It is
not unexpected that children and young people with,
for example, glomerular disease may need to spend
time on HD before transplantation is safe, but the
reasons for reduced pre-emptive transplantation in
children from ethnic backgrounds is unclear and needs
further study.
Current treatment modality is subject to variation over
time in the youngest children because of low patient
numbers in those age groups. It is interesting to note
that live kidney transplantation is more common than
deceased transplantation in younger children, with the
reverse ratio being seen in older children.
Primary renal disease
Structural renal disorders (renal dysplasia and
obstructive uropathy) accounted for half of all causes of
ERF. These children often present early in life, indeed
some are diagnosed antenatally, so spend many years
under paediatric nephrology care. Structural renal dis-
orders are more likely to be transplanted pre-emptively,
so perhaps we should be expecting to transplant a
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0.70
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Age 4–<8
Age 8–<12
Age 12–<16 Fig. 4.5. Unadjusted Kaplan-Meier
survival in the UK paediatric ERF
population ,16 years old starting RRT
between 2001 and 2014, by age at start
Table 4.16. Survival hazard ratio during childhood for the UK
paediatric ERF population ,16 years old, adjusted for age at
start of RRT, gender and RRT modality
Hazard ratio CI p-value
Age (years)
0–,2 4.1 1.7–9.9 0.002
2–,4 2.4 0.9–6.3 0.08
4–,8 2.7 1.1–7.0 0.04
8–,12 1.1 0.4–3.0 0.8
12–,16 1.0 – –
Gender
Female 1.3 0.7–2.2 0.4
Male 1.0 –
RRT modality
Dialysis 6.5 3.4–12.6 ,0.0001
Transplant 1.0 –
CI – conﬁdence interval
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greater number of children and young people pre-
emptively. Some missing data may be due to a PRD not
being assigned until the results of genetic tests have
been received.
The proportion of glomerular disease in the paediatric
RRT population has fallen by 10% since 2001–2005. With
UKRR data expanding to capture earlier stages of chronic
kidney disease (CKD) and resources such as the National
Registry of Rare Kidney Disease (RaDaR), it should be
possible to assess if better treatment is preserving renal
function for longer and whether there is a corresponding
increase in those with earlier stages of CKD due to
glomerular pathologies.
Knowing that AKI leads to signiﬁcant morbidity and
mortality, the UKRR has recently contributed to work
to prevent AKI nationally. Data on patients with AKI
are requested by the UKRR, but most paediatric units
are not yet in a position to provide those data, which
would help determine the contribution of AKI to ERF.
The current deﬁnitions of PRD do not pick up the
contribution of AKI; often the cause of ERF is multi-
factorial rather than related solely to the underlying
renal condition.
The incidence of renal disorders was higher in the
Asian, Black and ‘Other’ groups compared with White.
It would be interesting to look at PRD in these groups
to see if there are differences in renal diseases causing
ERF between populations.
Determining the representativeness of the comorbidity
data could be addressed by conﬁrming patient comorbid-
ity data with each centre using the 2015 data. On the
whole, it would appear that most paediatric patients
start RRT without comorbidity, but it is known reporting
varies by centre. It may be helpful to clarify the deﬁ-
nitions of comorbidities to aid more standardised
reporting.
The proportion of transplanted patients transferring
to adult services remained consistently high at approxi-
mately 90% and underpins the need for well-planned
transitions and transfers to ensure maximal long-term
graft survival.
Survival analysis continued to show the negative
inﬂuence of young age and dialysis modality. The rela-
tively small numbers of deaths on RRT will allow a
more detailed audit of deaths of children and young
people on RRT. Individual units will be contacted and
asked to provide more detailed information. This may
help to develop more informative cause of death cate-
gories. A project using UKRR data has involved further
survival analysis on a cohort of adolescents and young
adults starting RRT. This project has highlighted the
importance of transplant listing status on survival and
the results will be published shortly.
Current and future work
Several projects are planned for the forthcoming year.
A more detailed audit of deaths will be undertaken as
described above. Similarly, the need for better comor-
bidity reporting has been discussed. Further planned
work includes a report evaluating demographic and
clinical factors associated with graft function post trans-
plantation (evaluated as estimated glomerular ﬁltration
rate (eGFR)). An extended follow-up of a previously
reported cohort of children who commenced dialysis
aged under two years is also planned. This will provide
more relevant data with ﬁve to 10 year outcomes of UK
children.
Centres will be contacted with the aim of completing
comorbidity and disability data for prevalent patients
where this may have been submitted unclearly making
it impossible to differentiate between a condition being
not present in the patient or this information not being
available at the time of submission. Once complete it
will be possible to comment with more conﬁdence if
there are inter-centre differences in the rates of offering
RRT to patients with additional comorbidities.
There is well-documented unexplained between centre
variation in access to the waiting list, time taken for acti-
vation and receipt of a transplant once activated in both
adult and paediatric units. Following on from the success
of the Access to Transplantation and Transplant Out-
come Measures (ATTOM) project in adults, the Access
to Transplantation and Transplant Outcome Measures
In Children (ATTOMic) project will begin by focusing
on these aspects within paediatric nephrology centres,
initially based on the work of declined deceased donor
organs for prospective paediatric renal transplant recipi-
ents. The ﬁrst stage will be for a questionnaire to be
completed by the paediatric nephrologist or team caring
for any child (aged ,18 years) (i) on chronic dialysis;
(ii) renal transplant recipient but with eGFR ≤30 ml/
min/1.73 m2; or (iii) CKD with eGFR ≤30 ml/min/
1.73 m2. Data will be requested for all prevalent children
at each of the 13 paediatric nephrology centres on the
census date of 31st December 2016.
The expansion of UKRR data collection to include
CKD and AKI will widen the scope of our report and
give insights into such questions as whether PRD propor-
tions (for example glomerular disease, seen to be falling
in the ERF population) are changing due to improved
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management, delaying progression to ERF, as well as the
impact of AKI on CKD disease progression.
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